First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation

Author： von Felden Johann   Schulze Kornelius   Gil-Ibanez Ines   Werner Tobias   Wege Henning  

Publisher： MDPI

E-ISSN： 2075-4418|6|4|44-44

ISSN： 2075-4418

Source： Diagnostics, Vol.6, Iss.4, 2016-11, pp. : 44-44

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma

By Faltermeier Claire   Busuttil Ronald W.   Zarrinpar Ali  

Diseases, Vol. 3, Iss. 4, 2015-09 ,pp. : 221-252

MDPI

Access to resources Recommend Favorite

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

By Dumez Herlinde   Gallardo Enrique   Culine Stephane   Galceran Joan Carles   Schöffski Patrick   Droz Jean P.   Extremera Sonia   Szyldergemajn Sergio   Fléchon Aude  

Marine Drugs, Vol. 7, Iss. 3, 2009-09 ,pp. : 451-463

MDPI

Access to resources Recommend Favorite

Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

By  

Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma

By  

Chemotherapy, Vol. 60, Iss. 3, 2015-04 ,pp. : 201-210

Karger

Access to resources Recommend Favorite

Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future

By Koh Sarene   Tan Anthony Tanoto   Li Lietao   Bertoletti Antonio  

Diseases, Vol. 4, Iss. 1, 2016-02 ,pp. : 10-10

MDPI

Access to resources Recommend Favorite